N(1)-[1-[1-aryl-3-[4-(1H-imidazol-1-yl)phenyl]-3-oxo]propyl]-pyridine-2-carboxamidrazone derivatives were design, synthesized and tested for their in vitro antimycobacterial activity. The new compounds showed a moderate antimycobacterial activity against the tested strain of Mycobacterium tuberculosis H37Ra and a significant antimycobacterial activity against several mycobacteria other than tuberculosis strains.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.bmcl.2016.05.053 | DOI Listing |
Publication Analysis
Top Keywords
antimycobacterial activity
16
n1-[1-[1-aryl-3-[4-1h-imidazol-1-ylphenyl]-3-oxo]propyl]-pyridine-2-carboxamidrazone derivatives
8
antimycobacterial
4
activity n1-[1-[1-aryl-3-[4-1h-imidazol-1-ylphenyl]-3-oxo]propyl]-pyridine-2-carboxamidrazone
4
derivatives n1-[1-[1-aryl-3-[4-1h-imidazol-1-ylphenyl]-3-oxo]propyl]-pyridine-2-carboxamidrazone
4
derivatives design
4
design synthesized
4
synthesized tested
4
tested vitro
4
vitro antimycobacterial
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!